Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chicago, Illinois


Purpose:

Study to look at safety and effectiveness of different doses of tadalafil on prostate related genital/urinary tract problems.


Criteria:

Inclusion Criteria: - 6 month history of lower urinary tract symptoms either obstructive and/or irritative secondary to prostate related problems as diagnosed by a urologist. - Stopped using treatments at least four weeks prior to study and agree to not use any other treatments during the study. - Meet required prostate symptom score and urine flow rate. Exclusion Criteria: - Serum prostate specific antigen (PSA) greater than 10 (between 4 and 10, inclusive, without a negative biopsy w/in the last 6 months. - Prostate removal and various other pelvic surgeries. - Neurological disease or condition known to affect the bladder. - Clinical evidence of prostate cancer, urinary tract inflammation or infection, including prostatitis. - Have taken medications such as nitrates, finasteride, or dutasteride within the year.


NCT ID:

NCT00547625


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company


Backup Contact:

N/A


Location Contact:

Chicago, Illinois
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.